ArticleAnnals of medicine2025
The role of the transcription factor KLF16 in metabolic dysfunction associated fatty liver disease: regulatory linkages between lipid deposition and the expression of ATF4.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe escalating prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) poses a significant global health burden. MAFLD is characterized by abnormal lipid accumulation in liver parenchymal cells and activation of endoplasmic reticulum stress. However, the effect of Krüppel-like factor 16(KLF16) on glycolipid metabolism has been limited. We investigated whether KLF16 could alleviate MAFLD through endoplasmic reticulum stress.
methodsHepG2 and mouse primary hepatocytes were treated with oleic acid (OA) to model MAFLD
resultsKLF16 expression was upregulated in MAFLD models. KLF16 downregulation aggravates lipid deposition in liver cells. The expression of ATF4 protein was downregulated in MAFLD models with KLF16 knockdown. KLF16 transcriptionally regulates ATF4 expression through two binding sites. ATF4 overexpression alleviates lipid deposition exacerbated by KLF16 knockdown in mice.
conclusionIn the face of abnormal lipid deposition in MAFLD, liver cells can play a spontaneous protective role by upregulating KLF16, which can promote the expression of ATF4 at the transcriptional level, further affecting downstream lipid metabolism-related genes. KLF16 may serve as a promising target gene to improve the progression or prognosis of MAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.